AXAxinet
Menu
Finance

Live market screen

Commercial Space Company Risk / Opportunity Ranking

Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.

Updated June 27, 2026

Companies analyzed
438
Ranked rows
876
Evidence links
356
Rows per page
20

Opportunity view

Showing rows 101-120 of 438; 20 rows per page.

Sorted by raw opportunity score
RankCompanyScoreThesis / Evidence
101
Orbitworks
lowweak
Opp 4
Risk 2

Thesis: The reviewed sources' membership rationale says Orbitworks is an Abu Dhabi satellite integrator planning a 50-satellite AI-powered Earth observation constellation and participating in a SAR satellite program. If accurate and current, that implies meaningful long-horizon platform and constellation buildout opportunity, but the reviewed sources lack direct supporting summaries or available evidence.

Why now: The rationale references growth-oriented planned activity, which is relevant to a 1 year+ horizon, yet timing confidence is limited because coverage data shows no evidence after recent evidence window.

Caveats: Membership rationale references article IDs, and: but and article summaries are not provided in the reviewed sources. No direct positive_evidence or negative_evidence arrays are populated. Opportunity is based on stated plans, not validated conversion, contracts, or operating milestones inside the recent evidence window.

102
Overview Energy
lowweak
Opp 4
Risk 3

Thesis: Reviewed evidence rationale says Overview Energy won a U.S. Air Force contract for orbit-to-grid energy technology using geosynchronous satellites and space-based solar power. A defense contract in an ambitious emerging category is positive for strategic validation over a 1 year+ horizon.

Why now: The likely catalyst is the reported Air Force contract, yet the reviewed sources gives no retained article summary or evidence row to establish recency or contract scale.

Caveats: Phase2 membership rationale references: but no article summary or evidence are available. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

103
Pacific Defense
lowweak
Opp 4
Risk 3

Thesis: Reviewed evidence context says Pacific Defense launched the Moonraker payload, described as the first on-orbit demo of a reprogrammable payload for SSA/EMSO, developed under an AFRL contract. An on-orbit demo tied to a government contract is stronger business progress context than most peers in this screen and could support longer-horizon defense-space opportunity if follow-on adoption occurs.

Why now: The company appears more advanced than several peers because the reviewed sources references an on-orbit demo under contract, but there is no citable recency signal beyond membership support article ID: and no available evidence after recent evidence window.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary for citation. Opportunity score is relative within a weak-evidence batch, not high absolute conviction.

104
Portal Space Systems
lowweak
Opp 4
Risk 3

Thesis: Reviewed evidence rationale says Portal Space Systems raised a $50M Series A and offers commercial debris removal as a service with its Starburst spacecraft, which is directionally positive for a long-horizon growth thesis if validated.

Why now: Potential why-now would be the reported Series A and service positioning, but recency cannot be verified because no evidence are retained after the recent evidence window.

Caveats: Phase2 membership rationale references: but no article summary or evidence are included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Slightly higher opportunity than some peers only because the reviewed sources rationale mentions both financing and product/service positioning.

105
QOSMIC
lowweak
Opp 4
Risk 2

Thesis: QOSMIC has some opportunity potential because reviewed sources context says it raised about $3.3 million in seed funding to build optical communications infrastructure for space, with proceeds intended for engineering expansion, manufacturing scale-up, and deployment of optical communication terminals. That indicates an early-stage capital infusion tied to product buildout, but the evidence is undated and article-level rather than direct dated event evidence.

Why now: Why now is weak because the only support is undated context articles; the reviewed sources explicitly says no is available, so recency-sensitive claims should be treated cautiously for these funding and expansion statements

Evidence
  • Article summary says QOSMIC secured $3.33 million in seed funding led by Accel and Prosus, with investment to support engineering expansion, manufacturing scale-up and deployment of optical communication terminals. bwdisrupt.com
  • Article summary says Qosmic raised $3.3 million in seed funding to build optical communications infrastructure for space. startup.economictimes.indiatimes.com

Caveats: Evidence is undated; recency is uncertain. Support is supporting article context only, not direct structured positive event evidence. Same funding story appears in two articles and should not be treated as independent confirmation.

106
Quantum Space
lowweak
Opp 4
Risk 2

Thesis: The reviewed sources membership rationale says Quantum Space was selected by the U.S. Space Force for the Andromeda space monitoring satellite program. If current and material, that indicates credible government-program positioning in a strategically durable market.

Why now: The reviewed sources provide no post-recent evidence window detailed evidence, but the membership rationale specifically references selection for the Andromeda program via article. Because the underlying article summary/ is not included here, timing and magnitude are uncertain.

Caveats: No representative article or is included for the cited Andromeda selection evidence. Selection for a program is positive, but without award size or timing the business impact is unclear. Scores are capped by missing direct article-level support.

107
Sierra Nevada Corporation
mediummedium
Opp 4
Risk 2

Thesis: Sierra Nevada Corporation has the strongest available reviewed sources signal because a within the recent evidence window article says Space Systems Command awarded more than $1.8 billion in Andromeda contracts and included Sierra Space among the awarded companies, indicating participation in a potentially durable U.S. national-security space program if the Sierra Space/Sierra Nevada linkage holds.

Why now: The key surviving context is dated April 8, 2026, within the 90-day recent evidence window, and references recent contract awards under Andromeda that could matter over a 1 year+ horizon if they convert into meaningful program work. Article timestamp: April 8, 2026, basis: source date. Evidence is from at

Evidence
  • U.S. Space Force's Space Systems Command awarded 14 companies more than $1.8 billion in firm fixed price 'Andromeda' contracts; the listed companies include Sierra Space. April 8, 2026. defensedaily.com

Caveats: Evidence is supporting article context, not a direct structured positive event row for Sierra Nevada Corporation. Reviewed evidence explicitly notes entity-resolution ambiguity between Sierra Nevada Corporation and Sierra Space. The second representative article is older than the 90-day recent evidence window and should not drive recency, published September 2, 2025.

108
SpinLaunch
lowweak
Opp 4
Risk 4

Thesis: Reviewed evidence context says SpinLaunch's Meridian Space broadband constellation has 280 satellites being built. If accurate and current, that implies a tangible manufacturing/program buildout that could become strategically meaningful over a 1 year+ horizon.

Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation.

109
Starcloud
lowweak
Opp 4
Risk 2

Thesis: Starcloud has the strongest relative opportunity case in this screen, albeit still low-conviction, because the reviewed sources' membership rationale references a reported $170M Series A and orbital AI/data-center activity. For a 1 year+ horizon, fundraising plus infrastructure ambition could matter if execution follows, but the reviewed sources provide no direct positive evidence, no, and no validated chronology inside the recent evidence window.

Why now: If the fundraising and product positioning are recent, they could support a multi-quarter buildout story, but the reviewed sources explicitly shows zero available evidence after recent evidence window, so recency and sequencing cannot be confirmed.

Caveats: Most supportive facts appear only in membership rationale, not available evidence. Reported funding cannot be treated as fully validated without direct article support in reviewed sources. No, quote, or dated direct summary is available.

110
Stelleo
lowweak
Opp 4
Risk 2

Thesis: Stelleo has some opportunity appeal because recent company-context evidence positions it as a Polish Earth Observation startup turning satellite intelligence into operational decisions for infrastructure, agriculture, and environmental users across Europe, suggesting a commercially relevant application layer.

Why now: The article is within the recent evidence window and dated May 25, 2026, but it is a company-site style description rather than an independently reported business event, so it supports relevance more than momentum

Evidence
  • Article describes Stelleo as a Polish Earth Observation startup that turns satellite data into operational decisions and says it provides protection for infrastructure, harvests, and operations across Europe; May 25, 2026. stelleo.eu

Caveats: Evidence is article-level company context, not a direct commercial milestone. No direct traction, financing, or contract evidence is provided. Same-article repeated rows are not independent confirmation.

111
ThinkOrbital
lowweak
Opp 4
Risk 3

Thesis: ThinkOrbital has a speculative long-horizon opportunity signal because a dated May 2026 company-context article describes products spanning space domain awareness and in-space servicing, including ThinkX and a robotic arm/end effector. That suggests exposure to strategically important capability areas if the products convert into funded programs.

Why now: Why now is the dated company-context article from May 28, 2026, recent within the recent evidence window, but it is still weak grounding because it is article-level website context rather than a confirmed business event.

Evidence
  • Company-context article says ThinkX is 'the missing piece of space domain awareness' and ThinkToolkit is a robotic arm/end effector for in-space servicing, construction, inspection and military ops. Article timestamp May 28, 2026. thinkorbital.com

Caveats: Evidence is article-level website context, not direct contract or financing evidence. Single-source evidence limits corroboration. No dated proof of revenue, customer adoption, or deployment is included.

112
Viasat, Inc.
mediummedium
Opp 4
Risk 2

Thesis: Viasat has modest opportunity support from recent supporting article context showing it was selected as a prime contractor in the U.S. Space Force Protected Tactical Satcom-Global program and that Rocket Lab will supply the spacecraft bus for Viasat's PTS-G satellite, indicating active participation in a next-generation military satcom program.

Why now: Recent context exists within the recent evidence window: is dated June 11, 2026 and states Viasat was among operators selected under a combined $437.7 million award and has a defined supplier stack for its PTS-G satellite, which could matter over a 1 year+ horizon. Source date basis is source date.

Evidence
  • Rocket Lab will supply the spacecraft bus for Viasat’s PTS-G satellite, and the article says communications satellite operators SES and Viasat were selected as prime contractors under a combined $437.7 million award to each build and operate a satellite. spacenews.com

Caveats: This is supporting article context only; the reviewed sources classifies it under weak context, so it is weaker than direct event/fact evidence. Same article appears in two weak-context rows and should not be treated as independent confirmation. An older Viasat company-hosted article exists but is outside recent evidence window, February 29, 2024

113
Volta Space Technologies
lowweak
Opp 4
Risk 5

Thesis: Volta Space Technologies has an interesting long-horizon speculative opportunity because the reviewed sources rationale says it is developing a lunar laser power transmission system, with a 2028 demonstration planned and a payload booked on Firefly's Blue Ghost Mission 2.

Why now: The rationale cites article and says the company has a 2028 demonstration planned with payload booked on Blue Ghost Mission 2, which is relevant to a 1 year+ strategic horizon but weak for immediate evidence-based ranking because no article body or is visible.

Caveats: No visible representative article, quote, or in the reviewed sources body. The main cited demonstration is scheduled for 2028, so commercial payoff may sit beyond the stated 1 year+ ranking horizon. The Firefly payload linkage cannot be used as counterparty propagation evidence beyond the explicit rationale.

114
VyomIC
lowweak
Opp 4
Risk 3

Thesis: The membership rationale describes VyomIC as a Bengaluru-based New Space startup deploying a private global PNT satellite constellation in LEO, with first satellites planned for 2027 and 2028. That suggests large strategic upside over a 1 year+ horizon if financing and execution continue.

Why now: Why now is moderate only because the business is framed around future constellation deployment and milestone timing beyond the immediate term; however, recency cannot be validated because no recent evidence window evidence are available.

Caveats: Membership rationale cites article IDs and, but no are present. No representative article text or direct event/facts are available after the 90-day recent evidence window. Scoring reflects early-stage optionality and execution risk, not direct verified traction.

115
Wyvern
lowweak
Opp 4
Risk 4

Thesis: Wyvern has a plausible long-term opportunity in hyperspectral Earth observation. The reviewed sources say the company launched commercial hyperspectral satellites in 2023 and claims to be the only commercial provider with a ready-to-task constellation, which, if current, suggests existing capacity and differentiated imagery access.

Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing.

Evidence
  • Undated company-site context says Wyvern provides hyperspectral imaging and Earth observation data, launched commercial hyperspectral satellites in 2023, and is 'the only commercial provider with a ready-to-task constellation.' wyvern.space

Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown.

116
AAC Clyde Space AB
lowweak
Opp 3
Risk 3

Thesis: Membership rationale says AAC Clyde Space signed a EUR 10.9 million ESA contract for a 12-satellite VDES constellation, which would be meaningful positive evidence for a 1 year+ horizon if directly available, but these reviewed sources provide no surviving evidence or article summaries to substantiate the current state beyond the rationale reference (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract.

Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available.

117
Agnikul
lowweak
Opp 3
Risk 2

Thesis: Agnikul appears to have credible long-horizon opportunity potential because the reviewed sources places it among Indian spacetech beneficiaries and identifies it as 'launch infrastructure' in one summary, suggesting sector exposure that could matter over a year-plus horizon if operating milestones follow.

Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence.

Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window.

118
Arctus Aerospace
lowweak
Opp 3
Risk 2

Thesis: Arctus Aerospace has a modestly better long-horizon opportunity case than most peers in this screen because the reviewed sources rationale states it raised $2.6M and is developing HALE UAVs for earth observation, indicating financing plus product development progress (: no provided in reviewed sources).

Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts.

119
Astrolab
lowweak
Opp 3
Risk 3

Thesis: Reviewed evidence membership rationale says Astrolab received NASA moon-base/lunar-terrain-vehicle related contract support, which could be favorable over a 1 year+ horizon if active, but no available article evidence remains to support a stronger current ranking.

Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence.

Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate.

120
Axelspace Corporation
lowweak
Opp 3
Risk 3

Thesis: Membership rationale states Axelspace is launching seven GRUS-3 Earth observation microsatellites and expanding its constellation to more than 10 satellites, which would support an opportunity thesis tied to capacity expansion, but no direct evidence or article summaries are available in the reviewed sources after recent evidence window (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing.

Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields.

Risk view

Showing rows 421-438 of 438; 20 rows per page.

Sorted by raw risk score
RankCompanyScoreThesis / Evidence
421
Apparition Geoservices GmbH
lowweak
Opp 0
Risk 0

Thesis: No negative thesis can be established because no direct negative evidence for Apparition Geoservices GmbH is available in the reviewed sources after recent evidence filtering.

Why now: No current business-state change or catalyst is visible. Although 6 articles were considered, coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window, while the membership review says the reviewed sources are only a broad European tech funding roundup without a direct company-specific description.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Mention count and article count do not increase conviction because no post-recent evidence window evidence are available. Review-status rationale says retrieval context is insufficient for membership.

422
Arkeon
lowweak
Opp 0
Risk 0

Thesis: No negative thesis is supported because Arkeon has no direct negative evidence in the reviewed sources within the selected recent evidence window.

Why now: No company-specific timing signal is visible. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says only a generic funding-roundup article was available without a company-specific description tying Arkeon to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event, fact, or negative development is available after recent evidence window. Low membership confidence is not directional evidence.

423
Ars Magna Semiconductors
lowweak
Opp 0
Risk 0

Thesis: No negative thesis can be formed because the reviewed sources includes no direct negative evidence for Ars Magna Semiconductors within the recent evidence window.

Why now: There is no visible long-horizon strategic catalyst in the usable evidence. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a general tech funding roundup without a company-specific description linking the company to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct positive or adverse operating evidence is available. Generic roundup context is weaker than company-specific evidence and is not directional proof.

424
Augusta Labs
lowweak
Opp 0
Risk 0

Thesis: No negative thesis is supportable because the reviewed sources have no direct negative evidence for Augusta Labs after recent evidence filtering.

Why now: No current or durable catalyst can be identified from the reviewed sources. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says the company is only present in a generic funding-roundup article without direct identification against the listed criteria.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Absence of risk evidence is not positive evidence. No direct company-specific facts or events are available.

425
BeatpulseLabs
lowweak
Opp 0
Risk 0

Thesis: No negative thesis can be justified because no direct negative evidence for BeatpulseLabs is present in the reviewed sources within the recent evidence window.

Why now: There is no visible catalyst or deterioration signal. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a generic funding-roundup article with no direct company-specific connection to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event or fact evidence is available after recent evidence window. Generic context should not be treated as directional proof.

426
Bose Corporation
lowweak
Opp 0
Risk 0

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Bose Corporation after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 97 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; despite broad article consideration, nothing survived the time/evidence filters for a 1 year+ thesis judgment.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

427
Breaking Change
lowweak
Opp 0
Risk 0

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Breaking Change after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 3 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources gives no meaningful company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

428
CameraMatics
lowweak
Opp 0
Risk 0

Thesis: No negative thesis can be supported because there is no direct negative evidence for CameraMatics in the reviewed sources after recent evidence filtering.

Why now: No company-specific catalyst is visible despite 6 articles considered, because coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window. The membership note says the reviewed sources only includes CameraMatics in a generic funding roundup with no direct statement tying it to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Article count does not create conviction because no post-recent evidence window evidence are available. No direct positive or adverse company-specific event is available.

429
Camphouse
lowweak
Opp 0
Risk 0

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Camphouse after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

430
Capsa AI
lowweak
Opp 0
Risk 0

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Capsa AI after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

431
CardNexus
lowweak
Opp 0
Risk 0

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for CardNexus after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

432
CeQur
lowweak
Opp 0
Risk 0

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for CeQur after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

433
EaglePicher Technologies
lowweak
Opp 0
Risk 0

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse events or facts are retained after recent evidence window.

Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set.

434
IHI Corporation
lowweak
Opp 0
Risk 0

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse direct evidence remains after recent evidence window.

Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available.

435
OneWeb
lowweak
Opp 0
Risk 0

Thesis: No negative thesis is supportable from retained reviewed sources evidence because there are no direct negative evidence and no articles retained after the 90-day recent evidence window.

Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window.

Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity.

436
Starfighters Space Inc.
lowweak
Opp 0
Risk 0

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse evidence remains after the 90-day recent evidence window.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count.

Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence.

437
Starlab Space
lowweak
Opp 0
Risk 0

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no negative events or facts are retained after recent evidence window.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis.

438
Zone14
lowweak
Opp 0
Risk 0

Thesis: No negative thesis can be supported from the reviewed sources because there is no direct negative evidence available for Zone14 within the 90-day recent evidence window.

Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence.